NeuroSense Therapeutics Valuation
| NRSNW Stock | USD 0.21 0.01 5.00% |
NeuroSense Therapeutics seems to be overvalued based on Macroaxis valuation methodology. Our model forecasts the value of NeuroSense Therapeutics from analyzing the firm fundamentals such as Number Of Shares Shorted of 184, net income of (11.28 M), and Return On Equity of -4.95 as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that NeuroSense Therapeutics' price fluctuation is out of control at this time. Calculation of the real value of NeuroSense Therapeutics is based on 3 months time horizon. Increasing NeuroSense Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the NeuroSense stock is determined by what a typical buyer is willing to pay for full or partial control of NeuroSense Therapeutics Ltd. Since NeuroSense Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of NeuroSense Stock. However, NeuroSense Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.21 | Real 0.2 | Hype 0.21 | Naive 0.15 |
The intrinsic value of NeuroSense Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence NeuroSense Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of NeuroSense Therapeutics Ltd helps investors to forecast how NeuroSense stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of NeuroSense Therapeutics more accurately as focusing exclusively on NeuroSense Therapeutics' fundamentals will not take into account other important factors: NeuroSense Therapeutics Total Value Analysis
NeuroSense Therapeutics Ltd is now estimated to have takeover price of 0 with market capitalization of 0, debt of 142 K, and cash on hands of 994 K. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the NeuroSense Therapeutics fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
0 | 0 | 142 K | 994 K |
NeuroSense Therapeutics Asset Utilization
One of the ways to look at asset utilization of NeuroSense is to check how much profit was generated for every dollar of assets it reports. NeuroSense Therapeutics Ltd secures a negative usage of assets of -2.2 %, losing $0.022 for each dollar of assets held by the firm. Inadequate asset utilization conveys that the company is being less effective with each dollar of assets it secures. Strictly speaking, asset utilization of NeuroSense Therapeutics Ltd shows how discouraging it operates for each dollar spent on its assets.NeuroSense Therapeutics Profitability Analysis
Net Loss for the year was (11.28 M) with profit before overhead, payroll, taxes, and interest of 0.About NeuroSense Therapeutics Valuation
Our relative valuation model uses a comparative analysis of NeuroSense Therapeutics. We calculate exposure to NeuroSense Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of NeuroSense Therapeutics's related companies.NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for debilitating neurodegenerative diseases in Israel. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel. Neurosense Therapeutics is traded on NASDAQ Exchange in the United States.
NeuroSense Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as NeuroSense Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 13.6 M |
Additional Tools for NeuroSense Stock Analysis
When running NeuroSense Therapeutics' price analysis, check to measure NeuroSense Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NeuroSense Therapeutics is operating at the current time. Most of NeuroSense Therapeutics' value examination focuses on studying past and present price action to predict the probability of NeuroSense Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NeuroSense Therapeutics' price. Additionally, you may evaluate how the addition of NeuroSense Therapeutics to your portfolios can decrease your overall portfolio volatility.